"Overall, we met our revenue expectations for the quarter and remain confident in the second half growth drivers. We believe our discovery product lines will continue their strong performance, and with a healthy pipeline in imaging, expect to see full year growth in our imaging business of over 15%. In addition, CDAS revenues should strengthen considerably in the second half as we are optimistic regarding the next phase of the EPA ToxCast project," said Kevin Hrusovsky, president and CEO of Caliper. "Our strategic transformation toward higher-growth, higher-profit product lines is progressing and should enable sustained top-line performance. Additionally, we plan to further focus our resources in the second half to improve gross margins and operating efficiencies."
Adjusted net loss per share on a non-GAAP basis, as explained below under the heading "Use of Non-GAAP Financial Measures," was ($0.07) compared to ($0.03) for second quarter of 2007.
2008 GAAP Guidance
Caliper reported that its revenue outlook for the third quarter of 2008 is $33 to $36 million, and its revenue outlook for the full year remains $142 to $148 million.
Use of Non-GAAP Financial Measures
Caliper supplements its GAAP financial reporting with certain non-GAAP
financial measures. We use certain non-GAAP financial measures, including
adjusted EPS, which exclude restructuring charges, including severance
charges; amortization of acquired intangibles; asset impairment charges;
and amortization of stock compensation. We believe the presentation of
non-GAAP financial measures provides useful information to management and
investors regarding various financial and business trends relating to our
financial position and results of operations, and that when these non-GAAP
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved